No Data
Piper Sandler Maintains Olin(OLN.US) With Buy Rating, Cuts Target Price to $51
Olin Is Maintained at Market Perform by BMO Capital
Olin Biology (688319.SH): The proposed additional fundraising will not exceed 0.3 billion yuan.
Great Wisdom News on October 29th: Olin Biology (688319.SH) announced that the total amount of funds raised by the company in this stock issuance shall not exceed 175.2929 million yuan (including this amount), not exceeding 0.3 billion yuan and not exceeding 20% of the net assets at the end of the latest year. The net proceeds of the funds raised after deducting the relevant issuance expenses are intended to be invested in the following project: Vaccine research and production base technology renovation project.
Morgan Stanley Maintains Olin(OLN.US) With Sell Rating, Maintains Target Price $41
Express News | Olin Corp : BMO Cuts Target Price to $47 From $50
RBC Capital Maintains Olin(OLN.US) With Buy Rating, Cuts Target Price to $48
The Return Trends At Olin (NYSE:OLN) Look Promising
No Data
No Data
